Radiopharmaceutical developer FluoroPharma Medical is highlighting positive results presented this week for its CardioPET imaging agent.
The company said its ongoing phase II clinical trial of CardioPET for the assessment of coronary artery disease has shown positive results. Data were presented on February 6 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mid-Winter Meeting in Palm Springs, CA.
The results are encouraging for fatty acid imaging, presenter and study author Dr. Fabian Demeure said in a statement. CardioPET was well-tolerated and safely administered at Université Catholique de Louvain in Belgium, where part of the multicenter trial is being performed.
In addition, the agent showed rapid blood clearance with excellent image quality, and image time was within three minutes of injection, Demeure said.
The data are the first published on human use of the agent, added co-author Dr. Manuel Cerqueira from the Cleveland Clinic. "The dynamic aspects of fatty acid imaging are very interesting for the field of cardiac PET," he said.
